Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp61 | Bone development/growth and fracture repair | ECTS2014

Fas ligand in formation of hard tissues

Svandova Eva , Lesot Herve , Oralova Veronika , Poliard Anne , LeDenmat Dominique , Matalova Eva

Among activation of apoptotic machinery, Fas (CD95)/FasL (CD178) were suggested to act in cell proliferation and differentiation. Expression of Fas and FasL was reported during tooth and bone formation. The examination of gld mice showed increased total body bone mass and number of osteoblasts in long bones. However, Fas and FasL functions in osteogenesis remain controversial. As most of studies dealing with Fas/FasL system in bone formation were performed in endochondral mode...

ba0001pp71 | Bone development/growth and fracture repair | ECTS2013

Accuracy errors in longitudinal QCT measurements of cortical thickness bone mineral density and bone mineral content using different segmentation techniques: a simulation study

Gerner Bastian , Museyko Oleg , Topfer Dominique , Engelke Klaus

Introduction: The quantification of cortical BMD and thickness in QCT images remains challenging due to the limited spatial resolution of CT scanners. We simulated the impact of longitudinal cortical BMD and thickness changes on accuracy of cortical measurements using three different segmentation algorithms.Methods: A step function of varying width d (cortical thickness) and height (cortical BMD) and an additional step representing trabecular BMD was con...

ba0001pp140 | Cancer and bone: basic, translational and clinical | ECTS2013

NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and the tumor development in vivo

Gobin Berengere , Battaglia Severine , Chesneau Julie , Heymann Dominique

Osteosarcoma is the most common primary malignant bone tumor, characterized by osteoid production and/or osteolytic lesions of bone. Despite recent improvements in chemotherapy and surgery, the problem of non-response to chemotherapy remains and constitutes a poor prognosis parameter. Consequently new therapeutic strategies aim to improve the overall rate of survival. The present work investigated the therapeutic interest of a dual phosphatidylinositol-3-kinase (PI3K)/mammalia...

ba0003pp94 | Cancer and bone: basic, translational and clinical | ECTS2014

Preclinical efficacy of PF-04942847, a novel HSP90 inhibitor, in osteosarcoma

Lamoureux Francois , Baud'Huin Marc , Ory Benjamin , Heymann Dominique , Redini Francoise

Introduction and objective: Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to chemotherapy warrants the development of new strategies to improve overall patient survival. Among new therapeutic approaches, heat shock protein (HSP) 90 is a molecular chaperone involved in the maturation and stability of various oncogenic proteins leading to tumor cells survival. In this study, we assessed the in vitro a...

ba0003pp151 | Cell biology: osteoblasts and bone formation | ECTS2014

Syndecan-2 is a new negative modulator of Wnt signaling within bone marrow

Mansouri Rafik , Geoffroy Valerie , Marie Pierre , Modrowski Dominique

Wnt factors bind to heparan sulfate chains of syndecans that hence control their distribution in the cell microenvironment and also contribute to the internalization and recycling of the Wnt receptors. Syndecans are therefore likely important Wnt regulators within the bone marrow. Here, we investigated the interactions between Syndecan-2 and Wnt signaling in normal bone cells. We analyzed the effects of 2.3 kb Col1A1 promoter-driven Syndecan-2 overexpression in osteoblasts. Sy...

ba0001pp137 | Cancer and bone: basic, translational and clinical | ECTS2013

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma

Lamoureux Francois , Baud'huin Marc , Ory Benjamin , Gleave Martin , Heymann Dominique , Redini Francoise

Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to chemotherapy warrants new strategies still needed to improve overall patient survival. Among new therapeutic approaches, zoledronic acid represents a promising adjuvant molecule to chemotherapy to limit the osteolytic component of bone tumors. However, zoledronic acid triggers the elevation of heat shock proteins (Hsp), including Hsp27 and clusterin (CLU), whi...